Providing a molecular mechanism for P-glycoprotein; Why would i bother?

Richard Callaghan*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    31 Citations (Scopus)

    Abstract

    It is almost 40 years since the drug efflux pump P-glycoprotein (permeability glycoprotein or P-gp) was shown to confer multi-drug resistance in cancer cells. This protein has been one of the most extensively investigated transport proteins due to its intriguing mechanism and its affect in oncology. P-gp is known to interact with over 300 compounds and the ability to achieve this has not yet been revealed. Following the binding of substrate and nucleotide, a complex series of conformational changes in the membrane and cytosolic domains translocates substrate across the membrane. Despite over 30 years of biochemical investigation, the availability of structural data and a plethora of chemical tools to modulate its function, the molecular mechanism remains a mystery. In addition, overcoming its activity in resistant cancer cells has not been achieved in the clinic, thereby garnering some degree of pessimism in the field. This review highlights the progress that has been achieved in understanding this complex protein and the value of undertaking molecular studies.

    Original languageEnglish
    Pages (from-to)995-1002
    Number of pages8
    JournalBiochemical Society Transactions
    Volume43
    DOIs
    Publication statusPublished - 1 Oct 2015

    Fingerprint

    Dive into the research topics of 'Providing a molecular mechanism for P-glycoprotein; Why would i bother?'. Together they form a unique fingerprint.

    Cite this